b*****h
发帖数: 3386 | 1 这两天关注一下。 周六在ASCO上报告二期临床的结果
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting
of the American Society of Clinical Oncology
WALTHAM, Mass., May 21, 2009 (GlobeNewswire via COMTEX News Network) --
OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical
company developing novel therapeutics to treat cancer and eye diseases,
announced today that results from a Phase 2 clinical trial of its vascular
disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin), in
women with platinum-resistant ovarian cancer, will be presented in a
symposium at the upcoming 2009 Annual Meeting of the American Society of
Clinical Oncology (ASCO) in Orlando, FL, June 1, 2009. In addition, an
abstract describing clinical results from an ongoing Phase 1 trial in solid
tumors of OXi4503, the Company's second-generation, dual-mechanism drug
candidate, is published in the ASCO meeting program. OXiGENE will release a
summary of presented results on June 1, 2009. |
|
